For Atrial Fibrillation, DOACs Outperform Warfarin in Patients with Reduced Kidney Function

Area of Science:

• Pharmacology
• Nephrology
• Cardiology

Background:

• Direct oral anticoagulants (DOACs) are increasingly used for anticoagulation.
• Warfarin has been the traditional standard, but requires frequent monitoring.
• Understanding DOAC efficacy and safety across different kidney function levels is crucial.

Purpose of the Study:

• To compare the risks of systemic embolism and intracranial hemorrhage (ICH) between DOACs and warfarin.
• To evaluate the impact of DOAC dosage and creatinine clearance (CrCl) on clinical outcomes.
• To assess the association between lower-dose DOACs and mortality, ICH, and bleeding events.

Main Methods:

• Retrospective analysis of real-world data.
• Comparison of standard-dose DOACs versus warfarin.
• Analysis stratified by creatinine clearance (CrCl) levels down to 25 mL/min.
• Evaluation of lower-dose DOACs versus standard-dose DOACs and warfarin.

Main Results:

• Standard-dose DOACs showed reduced risks of systemic embolism and ICH compared to warfarin.
• This benefit was more pronounced at lower CrCl levels (down to 25 mL/min).
• Lower DOAC doses were linked to increased overall mortality without significant reductions in ICH or incident bleeding across all studied CrCl levels.

Conclusions:

• Standard-dose DOACs offer a favorable risk profile for embolism and ICH compared to warfarin, particularly in patients with impaired renal function.
• Lower DOAC doses should be used cautiously as they may increase mortality without providing commensurate safety benefits regarding bleeding or ICH.